Abstract
Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and its projections. Reports show a lower incidence of PD in smokers compared to nonsmokers. Nicotine reduce motor symptoms of patients already diagnosed with PD. However, the mechanisms underlying the effects of nicotine in the dopamine (DA) depleted striatum remain elusive. This study evaluates the effects of chronic nicotine administration on PD motor symptoms in an attempt to mimic the chronic self-administration of nicotine in smokers. To achieve this, we used the 6-OHDA hemiparkinson rat model evaluating the amphetamine/apomorphine induced circling behavior, in rats whose daily water intake included nicotine. We found that chronic nicotine reduced amphetamine (AMPH) induced circling behavior by 40%, whereas apomorphine (APO) increased this behavior by 230%. High-performance liquid chromatography (HPLC) revealed that AMPH produced a 50% decrease of DA release in the intact hemisphere, while on the striatum of the lesioned side, receptor binding assays showed an increased affinity to D1 receptors and a concurrent decrease in D2 receptors. c-Fos activity showed through double labeling, that cell types involved in nicotine action were low threshold (LTS) and fast spiking (FS) inter-neurons, which increased in the DA-depleted striatum. We also observed an increase in the activity of D1 medium spiny neurons (D1 MSN), a striatal population with a major role in motor control. Our results show that chronic nicotine does not specifically protect against degeneration, but rather modifies DA receptor dynamics, suggesting that it could be used as a therapeutic element in PD pathology.
Keywords: Basal ganglia, chronic nicotine, dopamine receptor, inter-neurons, Parkinson´s disease, striatum, neurodegenerative disorder, dopaminergic neurons, amphetamine, HPLC
CNS & Neurological Disorders - Drug Targets
Title:Is Nicotine Protective Against Parkinson´s Disease? An Experimental Analysis
Volume: 11 Issue: 7
Author(s): Jose-Ruben Garcia-Montes, Alejandra Boronat-Garcia, Ana-Maria Lopez-Colome, Jose Bargas, Magdalena Guerra-Crespo and Rene Drucker-Colin
Affiliation:
Keywords: Basal ganglia, chronic nicotine, dopamine receptor, inter-neurons, Parkinson´s disease, striatum, neurodegenerative disorder, dopaminergic neurons, amphetamine, HPLC
Abstract: Parkinson’s disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and its projections. Reports show a lower incidence of PD in smokers compared to nonsmokers. Nicotine reduce motor symptoms of patients already diagnosed with PD. However, the mechanisms underlying the effects of nicotine in the dopamine (DA) depleted striatum remain elusive. This study evaluates the effects of chronic nicotine administration on PD motor symptoms in an attempt to mimic the chronic self-administration of nicotine in smokers. To achieve this, we used the 6-OHDA hemiparkinson rat model evaluating the amphetamine/apomorphine induced circling behavior, in rats whose daily water intake included nicotine. We found that chronic nicotine reduced amphetamine (AMPH) induced circling behavior by 40%, whereas apomorphine (APO) increased this behavior by 230%. High-performance liquid chromatography (HPLC) revealed that AMPH produced a 50% decrease of DA release in the intact hemisphere, while on the striatum of the lesioned side, receptor binding assays showed an increased affinity to D1 receptors and a concurrent decrease in D2 receptors. c-Fos activity showed through double labeling, that cell types involved in nicotine action were low threshold (LTS) and fast spiking (FS) inter-neurons, which increased in the DA-depleted striatum. We also observed an increase in the activity of D1 medium spiny neurons (D1 MSN), a striatal population with a major role in motor control. Our results show that chronic nicotine does not specifically protect against degeneration, but rather modifies DA receptor dynamics, suggesting that it could be used as a therapeutic element in PD pathology.
Export Options
About this article
Cite this article as:
Garcia-Montes Jose-Ruben, Boronat-Garcia Alejandra, Lopez-Colome Ana-Maria, Bargas Jose, Guerra-Crespo Magdalena and Drucker-Colin Rene, Is Nicotine Protective Against Parkinson´s Disease? An Experimental Analysis, CNS & Neurological Disorders - Drug Targets 2012; 11 (7) . https://dx.doi.org/10.2174/1871527311201070897
DOI https://dx.doi.org/10.2174/1871527311201070897 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Macrophage Derived Cystatin B/Cathepsin B in HIV Replication and Neuropathogenesis
Current HIV Research Side Effects of Clozapine and Some Other Psychoactive Drugs
Current Drug Safety From Blood-to-Brain: Regulating the Permeability of the Blood-Brain Barrier
Current Psychopharmacology Cannabidiol Partially Blocks the Excessive Sleepiness in Hypocretindeficient Rats: Preliminary Data
CNS & Neurological Disorders - Drug Targets Bowel Habit in Preterm New borns: Effect of New Formulas
Endocrine, Metabolic & Immune Disorders - Drug Targets Voxel-Based Morphometry of the Human Brain: Methods and Applications
Current Medical Imaging Signal Transduction Pathways Provide Opportunities to Enhance HDL and apoAI-Dependent Reverse Cholesterol Transport
Current Pharmaceutical Biotechnology Propofol in Anesthesia. Mechanism of Action, Structure-Activity Relationships, and Drug Delivery
Current Medicinal Chemistry The Role of Nuclear Receptor PPARα in the Sleep-wake Cycle Modulation. A Tentative Approach for Treatment of Sleep Disorders
Current Drug Delivery Chemical Biology of mGlu4 Receptor Activation: Dogmas, Challenges, Strategies and Opportunities
Current Topics in Medicinal Chemistry Phospho-eIF4E: A New Target for Acute Myeloid Leukemia
Current Protein & Peptide Science T Lymphocytes as Targets of Gene Transfer with Moloney-Type Retroviral Vectors
Current Gene Therapy Recent Advances on Masticatory Robot
Recent Patents on Mechanical Engineering Diffusion Tensor Imaging to Determine Effects of Antidementive Treatment on Cerebral Structural Connectivity in Alzheimer’s Disease
Current Pharmaceutical Design A Perspective on Water Site Prediction Methods for Structure Based Drug Design
Current Topics in Medicinal Chemistry Aggresome Formation and Neurodegenerative Diseases: Therapeutic Implications
Current Medicinal Chemistry Extrasynaptic GABA<sub>A</sub> Receptors in the Brainstem and Spinal Cord: Structure and Function
Current Pharmaceutical Design Current Directions in Non-Invasive Low Intensity Electric Brain Stimulation for Depressive Disorder
CNS & Neurological Disorders - Drug Targets Epigenetic Drugs in Cognitive Disorders
Current Pharmaceutical Design Analysis of Glycosaminoglycans by Electrophoretic Approach
Current Pharmaceutical Analysis